Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232738 · ClinicalTrials.gov registry record · Phase 2
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Yunxia Wang, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 10
- Study locations
NCT01232738: Completed Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Yunxia Wang, MD.
NCT01232738 is a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS) that has completed, run by Yunxia Wang, MD. The registered enrollment target is 36 participants, below the 300-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01232738, a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), has completed, sponsored by Yunxia Wang, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 10
- Study locations
Study Summary
ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. While there are drugs to help relieve symptoms of ALS, there is no cure for ALS. Rasagiline is a drug with possible neuroprotective characteristics. Neuroprotective means that the nervous system may be protected against weakening. It is known that rasagiline has possible neuroprotective characteristics and it is approved for use for patients with another disorder, the effectiveness of rasagiline for patients with ALS has not been tested.
Primary Outcome
The primary outcome measure is the difference in the rate of decline in function, as detected by the ALS Functional Rating Scale - Revised (ALSFRS-R) in patients taking rasagiline compared to a database of patients from randomized clinical trials conducted during 1997-2007. Minimum score is 0 (no function) to Maximum score is 48 (normal function)
Conditions Studied
Interventions
- DRUG rasagiline
Study Locations (10)
Arizona
- Phoenix Neurological Institute - Phoenix
California
- California Pacific Medical Center - San Francisco
Iowa
- University of Iowa - Iowa City
Kansas
- University Of Kansas Medical Center - Kansas City
Minnesota
- University of Minnesota - Minneapolis
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- University of Tennessee - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01232738 record still lists
NCT01232738 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 300-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 1 intervention - of which rasagiline is the first listed.
NCT01232738 lists 10 locations in 10 states (Arizona, California, Iowa).
Frequently Asked Questions
What is clinical trial NCT01232738 about?
NCT01232738 is a clinical study titled "Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)". ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. While there are drugs to help relieve symptoms of ALS, there is no cure for ALS. Rasagili...
What is the current status of trial NCT01232738?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2011-12. Estimated completion is 2013-05.
What conditions does trial NCT01232738 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT01232738?
The interventions under investigation include: rasagiline (DRUG).
Who is sponsoring clinical trial NCT01232738?
This trial is sponsored by Yunxia Wang, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01232738 being conducted?
This trial has 10 study locations across Arizona, California, Iowa, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01232738's enrollment target sits among peer trials
36 16th of 18 higher than 3 of 18 other Amyotrophic Lateral Sclerosis (ALS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis (ALS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
-
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
ACTIVE NOT RECRUITING · Phase 2
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia